- Home
- Publications
- Publication Search
- Publication Details
Title
How we treat lower-risk myelodysplastic syndromes
Authors
Keywords
-
Journal
BLOOD
Volume 121, Issue 21, Pages 4280-4286
Publisher
American Society of Hematology
Online
2013-04-11
DOI
10.1182/blood-2013-02-453068
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.
- (2017) A. F. List et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
- (2012) R. S. Komrokji et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
- (2012) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
- (2012) Eunice S Wang et al. Journal of Hematology & Oncology
- Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry
- (2012) Judith Neukirchen et al. LEUKEMIA RESEARCH
- SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
- (2011) M. M. Patnaik et al. BLOOD
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
- (2011) L. Malcovati et al. BLOOD
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- (2011) P. Fenaux et al. BLOOD
- SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes
- (2011) M. G. Afable et al. BLOOD
- Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents
- (2011) David Sibon et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes
- (2011) Noémi B. A. Roy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
- (2011) L. Ades et al. HAEMATOLOGICA
- Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome
- (2011) Jaroslav Cermak et al. HEMOGLOBIN
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
- (2011) A A N Giagounidis et al. LEUKEMIA
- Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience
- (2011) Fabien Le Bras et al. LEUKEMIA RESEARCH
- Frequent pathway mutations of splicing machinery in myelodysplasia
- (2011) Kenichi Yoshida et al. NATURE
- SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts
- (2011) E. Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
- (2010) F. Thol et al. HAEMATOLOGICA
- Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
- (2010) Elaine M. Sloand et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99
- (2010) Jakob R. Passweg et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
- (2010) O Kosmider et al. LEUKEMIA
- Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
- (2010) Christian Rose et al. LEUKEMIA RESEARCH
- Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
- (2010) Norbert Gattermann et al. LEUKEMIA RESEARCH
- The lower risk MDS patient at risk of rapid progression
- (2010) Moshe Mittelman et al. LEUKEMIA RESEARCH
- Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
- (2010) Ramin Tehranchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
- (2009) V. Pullarkat BLOOD
- Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
- (2009) P. L. Greenberg et al. BLOOD
- TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
- (2009) O. Kosmider et al. BLOOD
- Impact of iron overload in myelodysplastic syndromes
- (2009) Pierre Fenaux et al. BLOOD REVIEWS
- Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children
- (2009) J W Lee et al. BONE MARROW TRANSPLANTATION
- Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia
- (2009) Véronique Gelsi-Boyer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
- (2009) P. Kirk et al. CIRCULATION
- Venous Thromboembolism in Myelodysplastic Syndrome Patients Receiving Lenalidomide
- (2009) Xionghu Yang et al. CLINICAL DRUG INVESTIGATION
- Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
- (2009) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
- (2009) Lanlan Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Myelodysplastic Syndromes
- (2009) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
- (2008) Cheng E. Chee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
- (2008) Aristoteles Giagounidis et al. ANNALS OF HEMATOLOGY
- Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)
- (2008) Uwe Platzbecker et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
- (2008) Y. Jiang et al. BLOOD
- Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
- (2008) Janice Gabrilove et al. BRITISH JOURNAL OF HAEMATOLOGY
- 250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
- (2008) A. J. Dunbar et al. CANCER RESEARCH
- Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
- (2008) Elaine M. Sloand et al. JOURNAL OF CLINICAL ONCOLOGY
- Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
- (2008) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes
- (2008) Matteo Giovanni Della Porta et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
- (2008) C. Kelaidi et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search